Hepatitis B vaccine boosting among young healthy adults

Safety and Immunogenicity of a Yeast-Derived Recombinant Hepatitis B Vaccine in Bulgarian Newborns

“…The high overall values of anti-HBsAg titers (> 100 mIU/ml in 92.9% and > 1,000 mIU/ml in 59.3%) obtained in immunized infants after the third dose of Euvax BTM suggest that a long-lasting presence of protective antiHBsAg level can be expected. Together with the effect of the immunologic memory, it can be predicted that this vaccine should induce long-lasting protection against disease [12][13][14][15].…”

A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B

“…Even if this limit does not take into account B and T memory cells, which can be actively recruited after HBV challenge, the determination of anti-HBs level in the serum is the only simple test available to monitor the decline of protection after vaccination and devise a booster policy. Several mathematical models have been proposed to predict the decay of antibody levels after vaccination, but all these studies were conducted on (i) a limited number of subjects [6] and/or serum samples [7]; (ii) a selected cluster of vaccine recipients (new-borns, homosexuals, adolescents, young adults) [8][9][10][11], introducing parameters which are known to influence the immune response (e.g. age, immunodeficiency, haemodialysis) [12][13][14].…”